Diagnosis and Treatment of Acute Lymphoblastic Leukemia Associated with Partial Deletion of the ERG Gene (SJ-08-0004)





Technology Name
(St. Jude Reference #)
Diagnosis and Treatment of Acute Lymphoblastic Leukemia Associated with Partial Deletion of the ERG Gene (SJ-08-0004)
Description In 2002 a new subtype of leukemia was identified at St. Jude through gene expression profiling.  More recently a genomic lesion in the ERG proto-oncogene that is responsible for this leukemic subtype has been discovered.  Definitive diagnostic assays for this subtype of leukemia are based on the identification of this lesion.  The altered ERG protein that results from this lesion contributes to cancer development and serves as a target for drug discovery.  A therapeutic targeting ERG may be useful for treating this leukemic subtype as well as other cancers since genetic abnormalities in the ERG gene have also been associated with prostate cancer and Ewing’s sarcoma. 
Keywords ERG, leukemia
Granted Patents or Published Applications International application published August 27, 2009 as WO 2009/105335
Related Scientific References Pending
Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: September 2008